OTCMKTS:SEOVF

Sernova News Headlines

$1.15
-0.01 (-0.86 %)
(As of 05/6/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.15
▼
$1.19
50-Day Range
$1.08
▼
$1.31
52-Week Range
$0.10
▼
$2.23
Volume15,060 shs
Average Volume134,926 shs
Market Capitalization$296.86 million
P/E RatioN/A
Dividend YieldN/A
Beta1.46

Headlines

Sernova (OTCMKTS SEOVF) News Headlines Today

SourceHeadline
Sernova (OTCMKTS:SEOVF) Trading Down 0.9%Sernova (OTCMKTS:SEOVF) Trading Down 0.9%
americanbankingnews.com - May 7 at 12:10 AM
Sernova Corp. (OTCMKTS:SEOVF) Short Interest UpdateSernova Corp. (OTCMKTS:SEOVF) Short Interest Update
americanbankingnews.com - April 15 at 1:08 AM
BTV News Alert Video: Sernova Corp. - A Functional Cure for Type I DiabetesBTV News Alert Video: Sernova Corp. - A Functional Cure for Type I Diabetes
finance.yahoo.com - February 5 at 10:01 PM
Sernova Corp. Announces C$10 Million Bought Deal Offering of UnitsSernova Corp. Announces C$10 Million Bought Deal Offering of Units
benzinga.com - February 3 at 5:38 PM
Investors flock to Canadian device maker Sernova hoping to transform how diabetes is treatedInvestors flock to Canadian device maker Sernova hoping to transform how diabetes is treated
theglobeandmail.com - January 21 at 10:18 PM
IIROC Trading Resumption - SVAIIROC Trading Resumption - SVA
finance.yahoo.com - January 15 at 5:39 PM
Bill Ackman Is Back in the Spotlight. Here’s an Overlooked Way to Invest in His Success.Bill Ackman Is Back in the Spotlight. Here’s an Overlooked Way to Invest in His Success.
finance.yahoo.com - August 28 at 8:33 AM
Sernova Corp. (SEOVF)Sernova Corp. (SEOVF)
ca.finance.yahoo.com - August 17 at 6:35 PM
Sernova to acquire cellular local immune protection technologySernova to acquire cellular local immune protection technology
seekingalpha.com - June 8 at 5:30 PM
Does The Sernova Corp. (CVE:SVA) Share Price Tend To Follow The Market?Does The Sernova Corp. (CVE:SVA) Share Price Tend To Follow The Market?
finance.yahoo.com - May 22 at 1:20 PM
Bill Ackman’s Fund Gained 58% Last Year. Why It Looks Like a Buy.Bill Ackman’s Fund Gained 58% Last Year. Why It Looks Like a Buy.
finance.yahoo.com - January 7 at 4:41 PM
Is Sernova (CVE:SVA) In A Good Position To Deliver On Growth Plans?Is Sernova (CVE:SVA) In A Good Position To Deliver On Growth Plans?
finance.yahoo.com - December 20 at 6:55 PM
Ackman’s New Mystery Bet Needs to Be More Exciting Than Buffett, According to AnalystAckman’s New Mystery Bet Needs to Be More Exciting Than Buffett, According to Analyst
finance.yahoo.com - November 5 at 1:31 PM
InvestmentPitch Media Video Discusses Sernova Corp's Further Validation of Cell Pouch and Therapeutic Cell Performance in Type-1 Diabetes - Video Available on Investmentpitch.comInvestmentPitch Media Video Discusses Sernova Corp's Further Validation of Cell Pouch and Therapeutic Cell Performance in Type-1 Diabetes - Video Available on Investmentpitch.com
finance.yahoo.com - October 17 at 12:24 PM
This page was last updated on 5/7/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.